- Home
- CRWD vs JNJ Comparison
CRWD vs JNJ Comparison
Compare CRWD & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRWD | JNJ |
|---|---|---|
| Founded | 2011 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.5B | 542.4B |
| IPO Year | 2019 | 2003 |
Fundamental Metrics
Financial Performance| Metric | CRWD | JNJ |
|---|---|---|
| Price | $675.88 | $232.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 48 | 20 |
| Target Price | ★ $507.00 | $238.20 |
| AVG Volume (30 Days) | 3.5M | ★ 5.9M |
| Earning Date | 06-02-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | 0.11 | ★ 2.14 |
| Revenue | ★ $4,812,005,000.00 | N/A |
| Revenue This Year | $24.85 | $6.63 |
| Revenue Next Year | $21.40 | $7.43 |
| P/E Ratio | $6,543.36 | ★ $106.65 |
| Revenue Growth | ★ 21.71 | N/A |
| 52 Week Low | $342.72 | $149.04 |
| 52 Week High | $785.66 | $251.71 |
Technical Indicators
Market Signals| Indicator | CRWD | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 59.78 | 57.14 |
| Support Level | $477.12 | $222.07 |
| Resistance Level | N/A | $235.50 |
| Average True Range (ATR) | 33.86 | 3.84 |
| MACD | 0.09 | 0.26 |
| Stochastic Oscillator | 46.13 | 83.66 |
Price Performance
Historical ComparisonAbout CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.